OrisDX Inc. Overview
Pro stress-test →OrisDX has developed a novel non-invasive salivary diagnostic test utilizing biomarker-based molecular genomic techniques to diagnose oral cavity cancers earlier. Founded from University of Chicago research, the startup addresses a critical clinical gap: currently, no oral cancer salivary diagnostics are endorsed by the American Dental Association, and the standard for detecting head and neck cancer is a biopsy, which often occurs at late stages and is associated with poorer patient outcomes.
Strategic Profile
Pro stress-test →OrisDX is a seed-stage biotech company with proven scientific pedigree and early validation. The company was formed based on a decade of research in the field of liquid biopsy and cancer genomics at the University of Chicago and Johns Hopkins University by top physicians and scientists. The company received a $250,000 Accelerator Award from the Chicago Biomedical Consortium in October 2025 to advance commercialization of its HPV oral cancer detection platform.
Competitive Landscape
Pro stress-test →OrisDX operates in diagnostic genomics but in a narrowly-defined vertical (salivary oral cancer detection). Broader competitors include molecular diagnostic platforms such as Guardant Health (liquid biopsy oncology) and GeneDx (genomic diagnostics), though these serve different patient populations and clinical workflows. Head-and-neck cancer diagnostics also rely on traditional biopsy workflows, giving OrisDX potential to disrupt standard-of-care.
Industry Context
OrisDX Inc. operates in Molecular diagnostic testing for oncology.
Key facts
Founded: 2023 or 2024 · Headquarters: Chicago, Illinois, United States · Employees: 5-9 · Revenue: Estimated pre-revenue or early-stage pilot revenue; specific figures not publicly disclosed · Market cap: N/A